History of Agenus in Timeline

By Popular Timelines Editorial Team · Updated: July 14, 2026

Agenus Inc. is a clinical-stage biotechnology company primarily focused on the development of novel immunotherapies to treat cancer. The company utilizes its proprietary platforms, including its antibody discovery engine and heat shock protein-based vaccines, to create therapeutic candidates. Its diverse pipeline features a wide array of immuno-oncology assets, such as checkpoint inhibitors, bispecific antibodies, and vaccine adjuvants designed to stimulate a robust immune response against tumors. Agenus frequently engages in strategic collaborations with major pharmaceutical companies to accelerate the development and commercialization of its oncology programs. By prioritizing complex immunotherapy combinations, Agenus aims to address significant unmet medical needs in the cancer treatment landscape, working toward more effective, personalized therapeutic options for patients battling various forms of malignancy.

1994: Founding of Agenus

In 1994, Garo H. Armen and Pramod K. Srivastava established the company originally known as Antigenics Inc., which would later become Agenus.

February 2000: Antigenics IPO

In February 2000, the company reached a major milestone by transitioning into a public entity, listing on the NASDAQ exchange under the ticker symbol AGEN.

March 2012: GSK Acquires Additional QS-21 Stimulon Rights

In March 2012, GlaxoSmithKline expanded its existing agreement with Agenus by acquiring two additional rights to use the QS-21 Stimulon adjuvant, which included a right of first negotiation for the potential purchase of Agenus or its assets.

October 2013: Efficacy Proof of QS-21 Stimulon

In October 2013, Agenus CEO Garo Armen announced that an 18-month follow-up study on the RTS,S malaria vaccine, which utilizes the QS-21 Stimulon adjuvant, demonstrated sufficient efficacy to move toward a regulatory filing.

October 2013: Positive Data for RTS,S Malaria Vaccine with QS-21 Stimulon

In October 2013, Agenus and GlaxoSmithKline announced that an 18-month follow-up study for the RTS,S malaria vaccine, which utilizes the QS-21 Stimulon adjuvant, produced positive results. The performance of the vaccine was deemed sufficient by GSK to move forward with regulatory filings for the treatment.

February 2014: Acquisition of 4-Antibody

In February 2014, Agenus expanded its biotechnological capabilities by acquiring the European firm 4-Antibody, securing their proprietary Retrocyte Display technology and a range of checkpoint modulator antibody candidates.

April 2014: Agenus and Merck Collaboration Agreement

In April 2014, Agenus entered into a strategic collaboration and licensing agreement with Merck to research and develop therapeutic antibodies targeting two specific checkpoint proteins associated with cancer treatment, utilizing Agenus's proprietary Retrocyte Display® technology to facilitate the discovery and optimization process.

2014: Regulatory Filing for RTS,S Malaria Vaccine

Following the positive results announced in 2013, a regulatory filing for the RTS,S malaria vaccine utilizing the QS-21 Stimulon adjuvant was planned and scheduled for 2014.

2017: Expiration of GSK Negotiation Rights

The rights acquired by GlaxoSmithKline in 2012 regarding the potential purchase of Agenus or its assets officially expired in 2017, marking the end of the five-year agreement period.

August 2023: Agenus Strategic Restructuring and Workforce Reduction

In August 2023, Agenus initiated a strategic restructuring plan to refocus its resources on the development of the botensilimab and balstilimab (BOT/BAL) clinical programs. As part of this transition, the company reduced its workforce by 25%, cutting approximately 85 positions, and temporarily paused various preclinical and clinical programs unrelated to the BOT/BAL combination. These measures were implemented to achieve an annual operating expense reduction of about $40 million.

June 2025: Strategic Collaboration between Agenus and Zydus Lifesciences

In June 2025, Agenus initiated a strategic partnership with Zydus Lifesciences valued at up to $141 million. The agreement involved the transfer of Agenus's manufacturing facilities in California to Zydus subsidiary Zylidac Bio LLC for $75 million, a $16 million equity investment, and the licensing of the botensilimab and balstilimab (BOT/BAL) combination therapy for specific markets.

2025: Agenus Divests CDMO Business and Partners with Zydus Lifesciences

In 2025, Agenus completed the sale of its CDMO business to Zydus Lifesciences, a transaction that encompassed two biologics manufacturing facilities located in Emeryville and Berkeley. Furthermore, in 2025, the two companies entered into a partnership agreement to commercialize Agenus's molecular assets within the Indian market.